Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- Essity's Business Categories Restructure: A Comprehensive Overview
- Taiwan Design Week 2025: Shaping a Future Through Design
- Essity Restructures Business Areas for Enhanced Growth Strategy
- Navigating the S&P 500: Returns and Future Predictions
- Foresight Group's Successful Share Buyback Initiative Details
- Katrin Aron's Leadership Extended to Enhance Customer Experience
- Capgemini Launches Innovative AI Tool for Youth Green Careers
- Nagarro Receives EcoVadis Gold Medal for Sustainability Achievement
- Lundbeck Showcases Promising Bexicaserin Data at AES 2025
- Lundbeck Unveils Promising Data on Bexicaserin for Epilepsy
- Nagarro Achieves Gold Medal for Sustainable Business Practices
- Nagarro Achieves Gold Medal for Business Sustainability Excellence
- Bairong Launches New HK$450 Million Share Buyback Initiative
- Exploring the Dynamics of the S&P 500 in 2026
- Record Black Friday Spending Indicates Economic Resilience
- MicroStrategy's Market Position and Future Outlook Unveiled
- Bullish Trends in Russell 2000 and S&P 500 Indices
- Bearish Trends in Japanese Stocks Amid BOJ Rate Speculation
- Strategic Partnership Between Statkraft and Hunton Fiber
- ASML's Latest Share Buyback Program: Key Insights Revealed
- ASML Holding N.V. Unveils Recent Buyback Program Transactions
- Transforming Rural Healthcare: Tata Elxsi's New Initiative
- Equinor ASA Announces Buy-Back Results for 2025 Tranche
- Aktsiaselts Infortar's Financial Reporting Schedule for 2026
- Elis Updates on Recent Share Buyback Activities
- Bavarian Nordic Announces Significant Share Buy-back Initiative
- Comprehensive Overview of Director Transactions at Octopus Apollo VCT
- Trump's Firm Rejection Leaves Maduro in a Tight Spot
- FTMO Unites with OANDA to Enhance Global Trading Landscape
- Endeavour Mining Sets Ambitious 5-Year Exploration Goals
- Allied Telesis Launches OneConnect: Transforming Network Management
- ZAGENO Earns Global Company of the Year Recognition in E-commerce
- Accord Healthcare Unveils New Denosumab Biosimilar for Bone Health
- Accord Healthcare Unveils New Biosimilars for Bone Health
- Top Dividend Stocks to Consider for Year-End Investment Gains
- Treasury Settlement Pressures Markets and Boosts Interest Rates
- BC.GAME Partners with Crypto Fight Night for 2025 Event
- Sampo plc Announces A Share Buyback Programme Update
- Ross Gerber Highlights Challenges in Tesla's FSD Technology
- Kalshi Unveils New Tokenized Predictions on Solana Network
- Dan Ives Projects $1 Trillion for Palantir In the Coming Years
- Paratus Energy Services Declares Dividend of USD 0.22 Today
- Paratus Energy Services Declares Ex Dividend of USD 0.22 Today
- MegazoneCloud Achieves Excellence with AWS Awards Again
- Paratus Energy Services Declares Latest Dividend Announcement
- GAC Introduces the Innovative AION V Electric SUV in Europe
- Revizto Launches Groundbreaking Tools for Infrastructure Projects
- iFlex Stretch Studios Enhances Wellness Offerings at Re-Opening
- Toobit Enhances Trader Experience with Altrady Integration
- Arcadis Reports Share Buyback Program Update for Investors
